Introduction: Recirculation (R), the shunting of arterial blood back into to the venous lumen, commonly occurs during veno-venous extracorporeal membrane oxygenation (VV-ECMO) and renders the monitoring of the venous line oxygen saturation no longer reflective of patient mixed venous oxygen saturation (S V O 2 ). Previously, we failed to prove the hypothesis that, once R is known, it is possible to calculate the S V O 2 of a patient on VV-ECMO. We hypothesize that we can calculate S V O 2 during VV-ECMO if we account for and add an additional correction factor to our model for dissolved oxygen content. Therefore, the purpose of this study is to derive a more accurate model that will allow clinicians to determine S V O 2 during VV-ECMO when ultrasound dilution is being used to quantify R. Methods: Using an extracorporeal circuit primed with fresh porcine blood, two stocks of blood were produced; (1) arterial blood (AB), and (2) venous blood (VB). To mimic recirculation, the AB and VB were mixed together in precise ratios using syringes and a stopcock manifold. Six paired stock AB/VB sets were prepared. Two sets were mixed at 20% R increments and 4 sets were mixed at 10% R increments. The partial pressure of oxygen (pO 2 ) and oxygen (O 2 ) saturation of the stock blood and resultant mixed blood was determined. The original model was modified by modeling the residual errors with linear regression. Results: When using the original model, as the partial pressure of arterial oxygen (P a O 2 ) of the stock AB increased, the calculated S V O 2 was higher than actual, especially at higher R levels. An iteration of the original model incorporating the P a O 2 level (low, medium, high) and R was derived to fit the data. Conclusions: The original model using R and circuit saturations for the calculation of S V O 2 in VV-ECMO patients is an oversimplification that fails to consider the influence of the high pO 2 of arterial blood during therapy. In the future, further improvements in this model will allow clinicians accurately to calculate S V O 2 in conjunction with recirculation measurements.
Introduction
Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is used for patients with respiratory failure, but without cardiac failure. Veno-arterial (VA) ECMO is used for patients with respiratory failure that may be associated with cardiac failure, or if it is thought that the patient will require cardiac support. Since the implementation of the dual lumen VV (DLVV) cannula in 1988, the use of VV-ECMO in the neonatal population has increased and encompasses about 32% of most noncardiac neonatal cases. 1, 2 Roberts et al. expanded VV-ECMO use to include patients whose cardiovascular system is mild to moderately dependent on inotropes for support. 3 Previously, these patients would have been placed on VA-ECMO. Recently, it also has been suggested that patients suffering from lung allograft failure may have better outcomes and fewer associated complications when using VV-ECMO as compared to traditional VA-ECMO. [3] [4] [5] [6] VV-ECMO alleviates certain risks that are associated with VA-ECMO, such as systemic embolization, ligation of the carotid artery, and cardiac stun syndrome. [7] [8] [9] One of the main technical problems that exist with VV-ECMO is recirculation. Recirculation in VV-ECMO can be defined as the fraction of oxygenated blood that is infused into the right atrium and is then aspirated back into the venous line of the ECMO circuit. 10, 11 It has been suggested that recirculation ranges from 20% to 50% when using the DLVV cannula. 11, 12 If the recirculated fraction is excessive, it can cause a decrease in the delivery of oxygen to the patient. In turn, this can cause an increase in pulmonary vascular resistance, an increase in myocardial demand, a decrease in myocardial oxygen supply, and a decrease in oxygen delivery to the body tissues, thus, initiating a vicious cycle. 13 A good indicator of the global perfusion status is the mixed venous oxygen saturation (S V O 2 ) of the blood returning to the right atrium which is, in turn, measured in the pulmonary artery by use of a catheter that allows either direct oximetry or blood sample aspiration for blood gas analysis. In cardiopulmonary bypass (CPB) and VA-ECMO, the saturation of the venous line (S VL O 2 ) is a true representation of S V O 2 and is used to direct the clinical care of patients. 14 With recirculation present in VV-ECMO, the value expressed as the S VL O 2 will always be an inaccurate measurement of S V O 2 . 10, 11 Currently, there is no way for clinicians to know, with any level of certainty, the S V O 2 of patients receiving VV-ECMO unless they turn off the sweep gas and allow the ECMO circuit to recirculate the native venous return. While this technique is useful when weaning a patient from VV-ECMO, some patients receiving this therapy are not stable enough simply to discontinue the sweep gas flow for evaluating S V O 2 . You can estimate the S V O 2 by sampling other major veins, such as the inferior vena cava or the internal jugular vein, 10 but these samples are regional values and do not accurately reflect global saturations. A change in venous line saturation can lead to certain assumptions which, if not correct, could lead to risky decisions; possibly having deleterious effects to an unstable patient. Currently, real-time venous line saturation on VV-ECMO provides trends in recirculation, disease progression/improvement, and cannula position.
Current ECMO literature has provided a mathematical model ( Figure 1 ) as a way to calculate recirculation. However, this model requires the use of a true venous saturation which does not exist in the VV-ECMO patient population. 10 Thus, it is more of a mathematical concept rather than an actual calculation of recirculation. The recirculation model was reconstructed by us in a previous study to solve for S V O 2 (see Figure 2 ). 11 However, this model requires the definition of recirculation. Recently, a method using dilutional ultrasound has been found to be accurate and beneficial for rapid bedside monitoring of recirculation in several swine models. 15, 16 In fact, the use of dilutional ultrasound recently has been used to quantify recirculation on a 5.8 kg neonate diagnosed with congenital diaphragmatic hernia. 17 With the development of dilutional ultrasound, we not only have a way to isolate recirculation, but also the possibility to solve for S V O 2 according to our model. Previously, we had hypothesized that, once recirculation was defined, we could accurately calculate S V O 2 using the derived original model. However, we found that the derived model did not adequately account for several factors affecting saturation and, therefore, was not accurate in calculating S V O 2 during VV-ECMO. 11 The factors that we believe need to be evaluated for their possible influences are pH, temperature, hemoglobin, and dissolved oxygen content. Therefore, the purpose of this bench top validation study is to evaluate our model further and improve upon it if possible.
Methods
Blood: One liter of fresh pig blood, collected in anticoagulant citrate dextrose (ACD), was used for this experiment. We used a small system, consisting of 1/4" tubing, a hard-shell reservoir, a Lilliput 1 oxygenator (Dideco, Sorin Group, Mirandola, Italy), and an HC 1400 hemoconcentrator (Sorin Group, Arvada, CA). The gas supplied to the oxygenator was a mixture of carbogen, nitrogen, carbon dioxide, and oxygen. This system allowed manipulation of blood partial pressures and saturations while maintaining a normal carbon dioxide pressure and an adequate acid-base balance. The system was used to create six simulated "patients." Each patient consisted of a venous and arterial blood source and had similar values of S V O 2 (64.7% ± 1.38%) and partial pressure of venous oxygen tension (36.3 mmHg ± 2.0 mmHg), but had varying values for partial pressure of oxygen (P a O 2 ), arterial blood saturation (S a O 2 ), and hemoglobin ( Table 1) . We had two groups with differing hemoglobin levels, but were unable to come to any conclusion due to the low number of patients in these two groups. We collected one 60 cc syringe of venous blood and one 60 cc syringe of arterial blood for each patient.
Recirculation Apparatus:
We used a nine-bay stopcock strip ( Figure 3) to facilitate the precise mixing of the blood samples. We attached a 10 cc waste syringe to the distal port, and nine 10 cc measurement syringes to the nine side-ports. The 60 cc syringe containing the venous blood was placed on the proximal end of the apparatus and was then advanced into each of the nine syringes in amounts ranging from 1 cc to 9 cc. The venous syringe was then removed and the 60 cc arterial blood syringe was attached. The main lumen of the system was flushed with the arterial blood into the waste syringe connected to the distal port. Each of the nine syringes was then filled to a total of 10 cc. Each of these syringes contained samples with fractions ranging from 10-90% or, in our case, percentage of recirculation. The first two of the six patients had recirculation measurements of 20%, 40%, 60%, 80%, and 90%. Upon further evaluation, we decided to decrease the recirculation increments to 10% Figure 3 . This is a picture of the mixture apparatus. This allowed precise mixing of the arterial and venous sources. to increase the number of data points per patient for evaluation. These methods were then followed for each of the subsequent patients.
Measurement Analysis:
Standard blood gas analysis and cooximetry for oxygen saturation and hemoglobin concentration were then performed on the arterial, venous, and resultant blood samples. The blood gas analyzer used was the Radiometer ABL 5 (Copenhagen, Denmark) and co-oximetry was done via a Radiometer OSM 3 (Copenhagen, Denmark). Standard blood gas values were recorded for this analysis.
Mathematical Analysis and Improvement:
The data that were collected were then presented to the Department of Biostatistics and Epidemiology for evaluation. The software used for all analyses was SAS Version 9.1.3 and R Version 2.5.1. For the first step, we used linear regression models, inspection of residuals, and linear regression modeling of residuals to evaluate the accuracy of Model 1 (Figure 4 ). We then used the same steps to modify the original model to fit the known values from the samples.
When comparing the differences between models, we quantified the variance by using root mean squared error (RMSE) and bias to characterize the precision and accuracy of estimation. We found that the original model had a RMSE of 12.96 and a bias of 8.37 ( Figure 5 ). We obtained Model 2 by correcting the residual error of Model 1 with a linear term [-(0.168*R)] for recirculation. For the second model, we found that we had a RMSE of 8.63 and a bias of -1.47 ( Figure 6 ). Upon further discussion and evaluation, it was evident that an additional factor was required to account for the interaction of R and P a O 2 . Model 3 (Figure 7 ) was the final model created. In this final model, there is a correction for P a O 2 in relation to R [-(0.163*R*P a O 2 )] as well as a correction for recirculation [-(0.005*R)]. The P a O 2 is not the exact number obtained from the blood gas analysis, but rather refers to ranges of P a O 2 . In the following table you will see the levels of P a O 2 that are present in our data set, and the associated number that is assigned and then input as the P a O 2 value (see Table 2 ). The final step involved reapplying the data set to the new model and comparing these values with the values produced by the original model.
Results
After subsequent evaluation and the addition of the correction terms to the model, the RMSE further improved from 8.63 to 4.03 and the bias from -1.47 to -0.9 (Figure 8) . When evaluating the models in a scatter plot on a 45 degree line, we can see the improvement from Model 2 to Model 3 (Figures 9-11 ).
Discussion
Other than our previous publication, 11 using both OVID MEDLINE and PUBMED, we were unable to locate research done in the area of mixing blood gases with varying contents of oxygen, and, more specifically, how varying levels of hemoglobin might effect the results. The dissolved oxygen content (0.003*pO 2 ) can be seen as a negligible amount, and under normal physiologic conditions accounts for less than 2% of the oxygen carried in the blood. In blood with a pO 2 of 100 mmHg, the dissolved oxygen content consists of 0.3 ml/dl, but when the pO 2 is 500 mmHg, the dissolved oxygen content is 1.5 ml/dl, which can account for about 9% of the total blood oxygen content. There is a significant difference between these two contents, which we have found to be as significant a factor as the recirculation fraction in being able to accurately calculate S V O 2 in VV-ECMO. It is this idea, that the dissolved oxygen content plays such an insignificant role and, therefore, does not require close evaluation, that causes problems. Under normal physiologic conditions, where mixing of venous and arterial blood does not occur, then it is true that the dissolved oxygen content plays an insignificant role. However, we have shown in this in vitro model that the dissolved oxygen content plays a significant role when attempting to estimate the resultant saturation of a sample comprised of two samples with vastly different oxygen saturations.
The original recirculation model (Figure 1) is quite simple and works with a P a O 2 <100 mmHg; however, it is oversimplified when the P a O 2 of the arterial line is elevated. In our experiment, we found that a P a O 2 of 482 mmHg greatly affects the S V O 2 calculated with the original model and that the result is quite inaccurate. We would infer the same conclusion for any P a O 2 value which is located on the plateau of the oxyhemoglobin dissociation curve.
This bench top study has resulted in a model that, in the future, could improve the outcome of patients being treated with VV-ECMO. As this concept is expounded upon and technology adapts, we can see the value of S V O 2 being obtained frequently for patients receiving VV-ECMO. Clinical decisions rightly could be made based on a sound, scientifically measured patient parameter. It would then be used in conjunction with current indicators to determine the efficacy of VV-ECMO. Some of these indicators are systemic lactate levels, near-infrared spectroscopy tissue oxygenation monitoring, and patient arterial/venous blood gas values. Fortunately, when a patient is on CPB or VA-ECMO, we do have a continuous in-line venous saturation monitor. If this monitor shows a decrease in venous saturation, the clinicians have information that could change their practice to benefit the patient. It seems that, with VV-ECMO, the providers have conceded to the fact that the value of S V O 2 holds very little clinical relevance. It is viewed as more of a trending device that should be closely scrutinized before any decisions can be made.
Being able accurately to measure S V O 2 in VV-ECMO patients could help identify when a patient requires conversion to VA-ECMO or, perhaps, it could be as simple as optimizing the patient position to minimize recirculation, giving inotrope support, or any other number of treatments to benefit the patient. At this time, any decisions made for these patients, based on S V O 2, is strictly based on conjecture.
The limitations of this study are: a complex mathematical model and theory, a lack of variability in the S V O 2 and a small number of "patients." Future studies should include a larger number of patients and a larger range of S V O 2 and hemoglobin. The equation published in this literature is still under development and has not yet been tested or validated in an animal or human model. This scatter plot shows that the variance and accuracy of Model 3 is dramatically improved when compared to Model 1.
